{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:07:44Z","timestamp":1790204864368,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01 DA045745"],"award-info":[{"award-number":["R01 DA045745"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R21 DA045848"],"award-info":[{"award-number":["R21 DA045848"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.sapharm.2024.02.001","type":"journal-article","created":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:18:41Z","timestamp":1707610721000},"page":"512-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["\u201cI go out of my way to give them an extra smile now:\u201d A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2086-4493","authenticated-orcid":false,"given":"Adriane N.","family":"Irwin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ventricelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse S.","family":"Boggis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Silcox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci C.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2024.02.001_bib1","series-title":"Data Briefs - Number 457","year":"2022"},{"issue":"23","key":"10.1016\/j.sapharm.2024.02.001_bib2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2115714119","article-title":"Modeling the evolution of the US opioid crisis for national policy development","volume":"119","author":"Lim","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.sapharm.2024.02.001_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183172","article-title":"The availability of pharmacies in the United States: 2007-2015","volume":"12","author":"Qato","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.sapharm.2024.02.001_bib4","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.japh.2022.07.003","article-title":"Access to community pharmacies: a nationwide geographic information systems cross-sectional analysis","volume":"62","author":"Berenbrok","year":"2022","journal-title":"J Am Pharmaceut Assoc"},{"issue":"6","key":"10.1016\/j.sapharm.2024.02.001_bib5","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamainternmed.2019.0272","article-title":"Association between state laws facilitating pharmacy distribution of naloxone and risk of fatal overdose","volume":"179","author":"Abouk","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.sapharm.2024.02.001_bib6","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/j.japh.2021.03.004","article-title":"Examining nonprescription syringe sales in Massachusetts and Rhode Island community pharmacies","volume":"61","author":"Green","year":"2021","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.japh.2019.06.016","article-title":"Pharmacist roles, training, and perceived barriers in naloxone dispensing: a systematic review","volume":"60","author":"Thakur","year":"2020","journal-title":"J Am Pharmaceut Assoc"},{"key":"10.1016\/j.sapharm.2024.02.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108597","article-title":"Pharmacists' nonprescription syringe dispensing perceptions and behaviors: a three-state descriptive analysis","volume":"221","author":"Hagemeier","year":"2021","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.sapharm.2024.02.001_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.sapharm.2022.09.002","article-title":"Pharmacists' naloxone services beyond community pharmacy settings: a systematic review","volume":"19","author":"Rawal","year":"2023","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib10","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/08897077.2021.2010162","article-title":"Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies","volume":"43","author":"Green","year":"2022","journal-title":"Subst Abuse"},{"issue":"2","key":"10.1016\/j.sapharm.2024.02.001_bib11","first-page":"35","article-title":"A participatory process to develop a naloxone, buprenorphine, and syringe safety interventions for community pharmacists. Proceedings of the Addiction Health Services Research (AHSR) 2020: virtual Conference: Part 2","volume":"15","author":"Green","year":"2020","journal-title":"Addiction Sci Clin Pract"},{"issue":"5","key":"10.1016\/j.sapharm.2024.02.001_bib12","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.japh.2020.03.005","article-title":"Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches","volume":"60","author":"Green","year":"2020","journal-title":"J Am Pharmaceut Assoc"},{"issue":"2S","key":"10.1016\/j.sapharm.2024.02.001_bib13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.japh.2017.01.013","article-title":"Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states","volume":"57","author":"Green","year":"2017","journal-title":"J Am Pharmaceut Assoc"},{"issue":"10","key":"10.1016\/j.sapharm.2024.02.001_bib14","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.sapharm.2019.12.023","article-title":"Development and pilot of a prescription drug monitoring program and communication intervention for pharmacists","volume":"16","author":"Alley","year":"2020","journal-title":"Res Soc Adm Pharm"},{"issue":"3","key":"10.1016\/j.sapharm.2024.02.001_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.japh.2019.11.030","article-title":"Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge","volume":"60","author":"Irwin","year":"2020","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.japh.2022.12.001","article-title":"Implementation of an academic detailing intervention to increase naloxone distribution and foster engagement in harm reduction from the community clinician","volume":"63","author":"Irwin","year":"2023","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib17","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.japh.2022.10.031","article-title":"Readiness of community pharmacies to implement an opioid safety intervention","volume":"63","author":"Floyd","year":"2023","journal-title":"J Am Pharmaceut Assoc"},{"key":"10.1016\/j.sapharm.2024.02.001_bib18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1186\/1756-0500-7-756","article-title":"Advantages of asynchronous online focus groups and face-to-face focus groups as perceived by child, adolescent and adult participants: a survey study","volume":"7","author":"Zwaanswijk","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.sapharm.2024.02.001_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/16094069221095658","article-title":"Using asynchronous online focus groups to capture healthcare professional opinions","volume":"21","author":"LaForge","year":"2022","journal-title":"Int J Qual Methods"},{"key":"10.1016\/j.sapharm.2024.02.001_bib20","year":"2023"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12874-019-0707-y","article-title":"Attempting rigour and replicability in thematic analysis of qualitative research data; a case study of codebook development","volume":"19","author":"Roberts","year":"2019","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.sapharm.2024.02.001_bib22","series-title":"Naturalistic Inquiry","author":"Lincoln","year":"1985"},{"issue":"10","key":"10.1016\/j.sapharm.2024.02.001_bib23","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.sapharm.2020.02.005","article-title":"Establishing trustworthiness and authenticity in qualitative pharmacy research","volume":"16","author":"Amin","year":"2020","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2024.02.001_bib24","year":"2016"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib25","first-page":"51","article-title":"Human rights, stigma, and substance use","volume":"22","author":"Wogen","year":"2020","journal-title":"Health Hum Rights"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12954-020-00399-8","article-title":"\u201cThey look at us like junkies\u201d: influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City","volume":"17","author":"Muncan","year":"2020","journal-title":"Harm Reduct J"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.japh.2019.09.007","article-title":"Impact of student pharmacist-led naloxone academic detailing at community pharmacies in Texas","volume":"60","author":"Evoy","year":"2020","journal-title":"J Am Pharmaceut Assoc"},{"issue":"3","key":"10.1016\/j.sapharm.2024.02.001_bib28","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.japh.2021.01.031","article-title":"Academic detailing with ambulatory pharmacists to support naloxone counseling","volume":"61","author":"Kennedy","year":"2021","journal-title":"J Am Pharmaceut Assoc"},{"issue":"5","key":"10.1016\/j.sapharm.2024.02.001_bib29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/1475-6773.13194","article-title":"Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration","volume":"54","author":"Bounthavong","year":"2019","journal-title":"Health Serv Res"},{"issue":"2S","key":"10.1016\/j.sapharm.2024.02.001_bib30","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/j.japh.2016.12.071","article-title":"Development and delivery of a pharmacist training program to increase naloxone access in Kentucky","volume":"57","author":"Palmer","year":"2017","journal-title":"J Am Pharmaceut Assoc"},{"issue":"4","key":"10.1016\/j.sapharm.2024.02.001_bib31","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/ajhp\/zxaa387","article-title":"Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order","volume":"78","author":"Santa","year":"2021","journal-title":"Am J Health Syst Pharm"},{"issue":"2","key":"10.1016\/j.sapharm.2024.02.001_bib32","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.japh.2022.12.018","article-title":"Pharmacists and naloxone: barriers to dispensing and effectiveness of an educational outreach program","volume":"63","author":"Hanson","year":"2023","journal-title":"J Am Pharmaceut Assoc"},{"issue":"1","key":"10.1016\/j.sapharm.2024.02.001_bib33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/add.15163","article-title":"Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States","volume":"116","author":"Smart","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.sapharm.2024.02.001_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.japh.2023.01.013","article-title":"\u201cLike it was just everyday business\u201d: a qualitative study of pharmacy-based naloxone and syringe customer experience","author":"Gray","year":"2023","journal-title":"J Am Pharmaceut Assoc"},{"issue":"5","key":"10.1016\/j.sapharm.2024.02.001_bib35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.japh.2020.01.030","article-title":"Evaluation of naloxone access, pricing, and barriers to dispensing in Tennessee retail community pharmacies","volume":"60","author":"Spivey","year":"2020","journal-title":"J Am Pharmaceut Assoc"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124000482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741124000482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:17:22Z","timestamp":1711639042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741124000482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1551741124000482"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.02.001","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cI go out of my way to give them an extra smile now:\u201d A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2024.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}